These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

269 related articles for article (PubMed ID: 27402198)

  • 21. Effect of combined chelation therapy with deferiprone and deferoxamine on left ventricular diastolic function in adult beta-thalassemia major patients.
    Tsiapras D; Fragatou S; Farmaki K; Kyrzopoulos S; Paraskevaidis I; Voudris V; Kremastinos D
    Hemoglobin; 2010 Jun; 34(3):210-20. PubMed ID: 20524811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Combined therapy with deferoxamine and deferiprone.
    Kattamis A
    Ann N Y Acad Sci; 2005; 1054():175-82. PubMed ID: 16339663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term safety and effectiveness of iron-chelation therapy with deferiprone for thalassemia major.
    Olivieri NF; Brittenham GM; McLaren CE; Templeton DM; Cameron RG; McClelland RA; Burt AD; Fleming KA
    N Engl J Med; 1998 Aug; 339(7):417-23. PubMed ID: 9700174
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Renal dysfunction in patients with beta-thalassemia major receiving iron chelation therapy either with deferoxamine and deferiprone or with deferasirox.
    Economou M; Printza N; Teli A; Tzimouli V; Tsatra I; Papachristou F; Athanassiou-Metaxa M
    Acta Haematol; 2010; 123(3):148-52. PubMed ID: 20185899
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical monitoring and management of complications related to chelation therapy in patients with β-thalassemia.
    Saliba AN; El Rassi F; Taher AT
    Expert Rev Hematol; 2016; 9(2):151-68. PubMed ID: 26613264
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Urinary iron excretion in young thalassemic patients receiving combined chelation treatment with deferoxamine and deferiprone.
    Christoforidis A; Zevgaridou E; Tsatra I; Perifanis V; Vlachaki E; Papassotiriou I; Apostolakou F; Athanassiou-Metaxa M
    J Pediatr Hematol Oncol; 2007 Sep; 29(9):598-601. PubMed ID: 17805032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Deferoxamine versus combined therapy for chelating liver, spleen and bone marrow iron in beta-thalassemic patients: a quantitative magnetic resonance imaging study.
    Drakonaki EE; Maris TG; Maragaki S; Klironomos V; Papadakis A; Karantanas AH
    Hemoglobin; 2010; 34(1):95-106. PubMed ID: 20113293
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Effects of green tea on iron accumulation and oxidative stress in livers of iron-challenged thalassemic mice.
    Saewong T; Ounjaijean S; Mundee Y; Pattanapanyasat K; Fucharoen S; Porter JB; Srichairatanakool S
    Med Chem; 2010 Mar; 6(2):57-64. PubMed ID: 20218965
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Potential myocardial iron content evaluation by magnetic resonance imaging in thalassemia major patients treated with Deferoxamine or Deferiprone during a randomized multicenter prospective clinical study.
    Galia M; Midiri M; Bartolotta V; Morabito A; Rizzo M; Mangiagli A; Malizia R; Borsellino Z; Capra M; D'Ascola DG; Magnano C; Gerardi C; Rigano P; Maggio A;
    Hemoglobin; 2003 May; 27(2):63-76. PubMed ID: 12779268
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Comparison of oral and subcutaneous iron chelation therapies in the prevention of major endocrinopathies in beta-thalassemia major patients.
    Wang CH; Wu KH; Tsai FJ; Peng CT; Tsai CH
    Hemoglobin; 2006; 30(2):257-62. PubMed ID: 16798651
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Deferiprone versus deferoxamine in thalassemia intermedia: Results from a 5-year long-term Italian multicenter randomized clinical trial.
    Calvaruso G; Vitrano A; Di Maggio R; Lai E; Colletta G; Quota A; Gerardi C; Rigoli LC; Sacco M; Pitrolo L; Maggio A
    Am J Hematol; 2015 Jul; 90(7):634-8. PubMed ID: 25809173
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Iron chelation therapy.
    Hershko CM; Link GM; Konijn AM; Cabantchik ZI
    Curr Hematol Rep; 2005 Mar; 4(2):110-6. PubMed ID: 15720959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    St Pierre TG
    Lancet; 2003 Jan; 361(9352):182; author reply 183-4. PubMed ID: 12531617
    [No Abstract]   [Full Text] [Related]  

  • 34. Effective new treatments of iron overload in thalassaemia using the ICOC combination therapy protocol of deferiprone (L1) and deferoxamine and of new chelating drugs.
    Kontoghiorghes GJ; Kolnagou A
    Haematologica; 2006 Jun; 91(6 Suppl):ELT04. PubMed ID: 16785141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy, compliance and toxicity factors are affecting the rate of normalization of body iron stores in thalassemia patients using the deferiprone and deferoxamine combination therapy.
    Kolnagou A; Kleanthous M; Kontoghiorghes GJ
    Hemoglobin; 2011; 35(3):186-98. PubMed ID: 21599431
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Deferiprone versus desferrioxamine in thalassaemia, and T2* validation and utility.
    Kontoghiorghes GJ; Kolnagou A
    Lancet; 2003 Jan; 361(9352):184. PubMed ID: 12531621
    [No Abstract]   [Full Text] [Related]  

  • 37. Iron chelation with oral deferiprone in patients with thalassemia.
    Cohen AR; Martin MB
    N Engl J Med; 1998 Dec; 339(23):1713-4. PubMed ID: 9867542
    [No Abstract]   [Full Text] [Related]  

  • 38. Risk/benefit assessment, advantages over other drugs and targeting methods in the use of deferiprone as a pharmaceutical antioxidant in iron loading and non iron loading conditions.
    Kontoghiorghes GJ; Efstathiou A; Kleanthous M; Michaelides Y; Kolnagou A
    Hemoglobin; 2009; 33(5):386-97. PubMed ID: 19814684
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Objectives and mechanism of iron chelation therapy.
    Hershko C; Link G; Konijn AM; Cabantchik ZI
    Ann N Y Acad Sci; 2005; 1054():124-35. PubMed ID: 16339658
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.
    Peng CT; Tsai CH; Wu KH
    Hemoglobin; 2008; 32(1-2):49-62. PubMed ID: 18274983
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 14.